Cytokinetics to Announce First Quarter Results on May 6, 2025
Cytokinetics (CYTK) has announced it will release its first quarter 2025 financial results on May 6, 2025, at 4:00 PM Eastern Time. Following the earnings release, the company's senior management will host a conference call at 4:30 PM Eastern Time to discuss the financial performance and provide business updates.
The conference call will be accessible through a simultaneous webcast from the Investors & Media section of Cytokinetics' website. Participants can also join via telephone by pre-registering through a provided link. A replay of the webcast will remain available on the company's website for six months.
Cytokinetics (CYTK) ha annunciato che pubblicherà i risultati finanziari del primo trimestre 2025 il 6 maggio 2025 alle 16:00 ora della costa orientale degli Stati Uniti. Dopo la pubblicazione dei risultati, il management senior dell'azienda terrà una conference call alle 16:30 ora della costa orientale per discutere le performance finanziarie e fornire aggiornamenti sul business.
La conference call sarà accessibile tramite un webcast simultaneo nella sezione Investitori e Media del sito web di Cytokinetics. I partecipanti potranno anche unirsi telefonicamente previa registrazione tramite un link fornito. La registrazione del webcast resterà disponibile sul sito aziendale per sei mesi.
Cytokinetics (CYTK) ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el 6 de mayo de 2025 a las 4:00 PM hora del Este. Tras la publicación de los resultados, la alta dirección de la empresa realizará una conferencia telefónica a las 4:30 PM hora del Este para discutir el desempeño financiero y ofrecer actualizaciones comerciales.
La conferencia telefónica será accesible mediante una transmisión simultánea en la sección de Inversores y Medios del sitio web de Cytokinetics. Los participantes también podrán unirse por teléfono registrándose previamente a través de un enlace proporcionado. La grabación de la transmisión estará disponible en el sitio web de la empresa durante seis meses.
Cytokinetics (CYTK)는 2025년 5월 6일 오후 4시(동부 표준시)에 2025년 1분기 재무 결과를 발표할 예정입니다. 실적 발표 후, 회사의 고위 경영진이 오후 4시 30분(동부 표준시)에 컨퍼런스 콜을 진행하여 재무 성과를 논의하고 사업 현황을 업데이트할 예정입니다.
컨퍼런스 콜은 Cytokinetics 웹사이트의 투자자 및 미디어 섹션에서 실시간 웹캐스트로 접속할 수 있습니다. 참가자는 제공된 링크를 통해 사전 등록 후 전화로도 참여할 수 있습니다. 웹캐스트 녹화본은 회사 웹사이트에 6개월 동안 게시됩니다.
Cytokinetics (CYTK) a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le 6 mai 2025 à 16h00, heure de l'Est. Après la publication des résultats, la haute direction de l'entreprise tiendra une conférence téléphonique à 16h30, heure de l'Est, pour discuter des performances financières et fournir des mises à jour sur les activités.
La conférence téléphonique sera accessible via une diffusion simultanée dans la section Investisseurs & Médias du site web de Cytokinetics. Les participants pourront également se joindre par téléphone en s'inscrivant préalablement via un lien fourni. Le replay de la diffusion restera disponible sur le site de l'entreprise pendant six mois.
Cytokinetics (CYTK) hat angekündigt, dass die Finanzergebnisse für das erste Quartal 2025 am 6. Mai 2025 um 16:00 Uhr Eastern Time veröffentlicht werden. Im Anschluss an die Ergebnisveröffentlichung wird das Senior-Management des Unternehmens um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die finanzielle Leistung zu besprechen und Geschäftsinformationen zu geben.
Die Telefonkonferenz ist über einen simultanen Webcast im Bereich Investoren & Medien auf der Website von Cytokinetics zugänglich. Teilnehmer können auch telefonisch teilnehmen, wenn sie sich über einen bereitgestellten Link vorab registrieren. Eine Aufzeichnung des Webcasts wird für sechs Monate auf der Unternehmenswebsite verfügbar bleiben.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.
The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cytokinetics Q1 2025 Earnings Conference Call. Upon registration, participants will receive a dial-in number and a unique passcode to access the call. An archived replay of the webcast will be available via Cytokinetics’ website for six months.
About Cytokinetics
Cytokinetics is a specialty biopharmaceutical company building on its over 25-years of pioneering scientific innovation with intention to create a muscle biology franchise business focused on medicines designed to optimize muscle performance for patients with cardiac and other diseases of muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When will Cytokinetics (CYTK) report Q1 2025 earnings?
How can investors access Cytokinetics' Q1 2025 earnings call?
What time is CYTK's Q1 2025 earnings conference call?
How long will CYTK's Q1 2025 earnings call replay be available?
